Volume 82, Issue 12, Pages 1297-1303 (December 2012) Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients  Sophie Liabeuf, Aurélie Lenglet, Lucie Desjardins, Nathalie Neirynck, Griet Glorieux, Horst-Dieter Lemke, Raymond Vanholder, Momar Diouf, Gabriel Choukroun, Ziad A. Massy  Kidney International  Volume 82, Issue 12, Pages 1297-1303 (December 2012) DOI: 10.1038/ki.2012.301 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 1 Plasma beta-2 microglobulin levels as a function of chronic kidney disease (CKD) stage. *P<0.0001 vs. control group; **P<0.0001 vs. CKD stages 2 and 3; and ***P<0.0001 vs. CKD stages 4 and 5. Kidney International 2012 82, 1297-1303DOI: (10.1038/ki.2012.301) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 2 Exponential relationship between plasma beta-2 microglobulin level and estimated glomerular filtration rate, predialysis chronic kidney disease stages 2–5 (n=96, r2=0.789, P<0.0001). Kidney International 2012 82, 1297-1303DOI: (10.1038/ki.2012.301) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 3 Kaplan–Meier estimates of the probability of cardiovascular event-free survival for the subgroup of predialysis patients, as a function of median plasma beta-2 microglobulin concentration. Results were adjusted for propensity score, which included age, albumin, C-reactive protein, hemoglobin, and phosphate levels, aortic calcification score, and estimated glomerular filtration rate. Kidney International 2012 82, 1297-1303DOI: (10.1038/ki.2012.301) Copyright © 2012 International Society of Nephrology Terms and Conditions